Generation and maturation of dendritic cells for clinical application under serum-free conditions

Journal of Immunotherapy

Volumn 28, Issue 6, 2005, Pages 599-609

  Peng, Judy C ^a   Thomas, Ranjeny ^a   Nielsen, Lars K ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Anti interleukin 10; Dendritic cells; Immunotherapy; Serum free medium

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROSTAGLANDIN E2; RIBOMUNYL; TETANUS TOXOID; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CELL MATURATION; CULTURE MEDIUM; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSTIMULATION; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 27444438996     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000175491.21099.04     Document Type: Article

References (57)

1. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med. 1999;50:507-529.
2. Mackensen A, Drager R, Schlesier M, et al. Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells. Cancer Immunol Immunother. 2000;49:152-156.
3. Jonuleit H, Giesecke-Tuettenberg A, Tuting T, et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer. 2001;93:243-251.
4. Rutkowski P, Kaminska J, Kowalska M, et al. Cytokine serum levels in soft tissue sarcoma patients: Correlations with clinico-pathological features and prognosis. Int J Cancer. 2002;100:463-471.
5. Hayashi T, Hideshima T, Akiyama M, et al. Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood. 2003;102:1435-1442.
6. Kurzrock R. Cytokine deregulation in cancer. Biomed Pharmacother. 2001;55:543-547.
7. Romani N, Reider D, Heuer M, et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods. 1996;196:137-151.
8. Holtl L, Zelle-Rieser C, Gander H, et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res. 2002;8:3369-3376.
9. O'Rourke MGE, Johnson M, Lanagan C, et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother. 2003;52:387-395.
10. Tarte K, Fiol G, Rossi JF, et al. Extensive characterization of dendritic cells generated in serum-free conditions: Regulation of soluble antigen uptake, apoptotic tumor cell phagocytosis, chemotaxis and T cell activation during maturation in vitro. Leukemia. 2000;14:2182-2192.
11. Abdel-Wahab Z, DeMatos P, Hester D, et al. Human dendritic cells, pulsed with either melanoma tumour cell lysates or the gp100 pepetide (280-288), induce pairs of T cell cultures with similar phenotype and lytic activity. Cell Immunol. 1998;186:63-74.
12. Thurner B, Roder C, Dieckmann D, et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods. 1999;223:1-15.
13. + T cells through 1L-12 produced by Listeria-induced macrophages. Science. 1993;260:547-549.
14. Szabo SJ, Sullivan BM, Peng SL, et al. Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol. 2003;21:713-758.
15. Parronchi P, De Carli M, Manetti R, et al. IL-4 and IFN (α and γ) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones. J Immunol. 1992;149:2977-2983.
16. Manetti R, Parronchi P, Giudizi MG, et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med. 1993;177:1199-1204.
17. + T cells acts in an autocrine manner to induce Th2 differentiation. Eur J Immunol. 2002;32:1428-1433.
18. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest (Suppl). 1968;97:77-89.
19. Smithers M, O'Connell K, MacFadyen S, et al. Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen. Cancer Immunol Immunother. 2003;52:41-52.
20. Panelli MC, Wunderlich J, Jeffries J, et al. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J Immunother. 2000;23:487-498.
21. Hayes MP, Wang J, Norcross MA. Regulation of interleukin-12 expression in human monocytes: Selective priming by interferon-γ of lipopolysaccharide-inducible p35 and p40 genes. Blood. 1995;86:646-650.
22. Verdijk RM, Mutis T, Esendam B, et al. Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. J Immunol. 1999;163:57-61.
23. Boccaccio C, Jacod S, Kaiser A, et al. Identification of a clinical-grade maturation factor for dendritic cells. J Immunother. 2002;25:88-96.
24. Jonuleit H, Kuhn U, Muller G, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatoiy dendritic cells under fetal calf serum-free conditions. Eur J Immunol. 1997;27: 3135-3142.
25. Vieira PL, de Jong EC, Wierenga EA, et al. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol. 2000;164:4507-4512.
26. Hochrein H, O'Keeffe M, Luft T, et al. Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells. J Exp Med. 2000;192:823-833.
27. Corinti S, Albanesi C, la Sala A, et al. Regulatory activity of autocrine IL-10 on dendritic cell functions. J Immunol. 2001;166:4312-4318.
28. Schnurr M, Toy T, Shin A, et al. Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and enhances IL-23 expression in human dendritic cells: A novel role for the cAMP pathway. Blood. 2005;105: 1582-1589.
29. Duperrier K, Eljaafari A, Dezutter-Dambuyant C, et al. Distinct subsets of dendritic cells resembling dermal DCs can be generated in vitro from monocytes, in the presence of different serum supplements. J Immunol Methods. 2000;238:119-131.
30. Grohmann U, Belladonna ML, Bianchi R, et al. IL-12 acts directly on DC to promote nuclear localization of NF-kB and primes DC for IL-12 production. Immunity. 1998;9:315-323.
31. Re F, Strominger J L. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem. 2001;276:37692-37699.
32. Weigt H, Muhlradt PF, Emmendorffer A, et al. Synthetic mycoplasma-derived lipopeptide MALP-2 induces maturation and function of dendritic cells. Immunobiology. 2003;207:223-233.
33. Agrawal S, Agrawal A, Doughty B, et al. Cutting edge: Different toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen- activated protein kinase and c-Fos. J Immunol. 2003;171: 4984-4989.
34. Huang Q, Liu D, Majewski P, et al. The plasticity of dendritic cell responses to pathogens and their components. Science. 2001;294:870-875.
35. Edwards AD, Manickasingham SP, Sporri R, et al. Microbial recognition via Toll-like receptor-dependent and -independent pathways determines the cytokine response of murine dendritic cell subsets to CD40 triggering. J Immunol 2002;169:3652-3660.
36. Mosca PJ, Hobeika AC, Clay TM, et al. A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-γ treatment. Blood. 2000;96: 3499-3504.
37. Caux C, Massacrier C, Vanbervliet B, et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med. 1994;180:1263-1272.
38. Lee BO, Haynes L, Eaton SM, et al. The biological outcome of CD40 signaling is dependent on the duration of CD40 ligand expression: Reciprocal regulation by interleukin (IL)-4 and IL-12. J Exp Med. 2002; 196:693-704.
39. Bianchi R, Grohmann U, Vacca C, et al. Autocrine IL-12 is involved in dendritic cell modulation via CD40 ligation. J Immunol. 1999;163:2517-2521.
40. O'Sullivan BJ, Thomas R. CD40 ligation conditions dendritic cell antigen-presenting function through sustained activation of NF-kB. J Immunol. 2002;168:5491-5498.
41. Ria F, Penna G, Adorini L. Th1 cells induce and Th2 inhibit antigen-dependent IL-12 secretion by dendritic cells. Eur J Immunol. 1998;28: 2003-2016.
42. Martin E, O'Sullivan B, Low P, et al. Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10. Immunity. 2003;18:155-167.
43. Sun W, Wang Q, Zhang L, et al. Blockade of CD40 pathway enhances the induction of immune tolerance by immature dendritic cells genetically modified to express cytotoxic T lymphocyte antigen 4 immunoglobulin. Transplantation. 2003;76:1351-1359.
44. Kaisho T, Hoshino K, Iwabe T, et al. Endotoxin can induce MyD88-deficient dendritic cells to support Th2 cell differentiation. Int Immunol. 2002;14:695-700.
45. Kalinski P, Hilkens CM, Snijders A, et al. IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. J Immunol. 1997;159: 28-35.
46. + dendritic cells to produce type I IFN. J Immunol. 2001;166:2291-2295.
47. Doyle SE, O'Connell R, Vaidya SA, et al. Toll-like receptor 3 mediates a more potent antiviral response than toll-like receptor 4. J Immunol. 2003;170:3565-3571.
48. Zou W, Borvak J, Wei S, et al. Reciprocal regulation of plasmacytoid dendritic cells and monocytes during viral infection. Eur J Immunol. 2001;31:3833-3839.
49. Gary-Gouy H, Lebon P, Dalloul AH. Type I interferon production by plasmacytoid dendritic cells and monocytes is triggered by viruses, but the level of production is controlled by distinct cytokines. J Interferon Cytokine Res. 2002;22:653-659.
50. Heystek HC, den Drijver B, Kapsenberg ML, et al. Type I IFNs differentially modulate IL-12p70 production by human dendritic cells depending on the maturation status of the cells and counteract IFNγ-mediated signaling. Clin Immunol. 2003;107:170-177.
51. McRae BL, Semnani RT, Hayes MP, et al. Type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development. J Immunol. 1998;160:4298-4304.
52. D'Andrea A, Aste-Amezaga M, Valiante NM, et al. Interleukin 10 (IL-10) inhibits human lymphocyte interferon γ-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med. 1993;178:1041-1048.
53. Brossart P, Zobywalski A, Grunebach F, et al. Tumor necrosis factor-α and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells. Cancer Res. 2000;60:4485-4492.
54. MacDonald KP, Pettit AR, Quinn C, et al. Resistance of rheumatoid synovial dendritic cells to the immunosuppressive effects of IL-10. J Immunol. 1999;163:5599-5607.
55. Luft T, Jefford M, Luetjens P, et al. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E2 regulates the migratory capacity of specific DC subsets. Blood. 2002;100: 1362-1372.
56. Takayama T, Morelli AE, Onai N, et al. Mammalian and viral IL-10 enhance C-C chemokine receptor 5 but down-regulate C-C chemokine receptor 7 expression by myeloid dendritic cells: Impact on chemotactic responses and in vivo homing ability. J Immunol. 2001;166:7136-7143.
57. Watanabe S, Kagamu H, Yoshizawa H, et al. The duration of signaling through CD40 directs biological ability of dendritic cells to induce antitumor immunity. J Immunol. 2003;171:5828-5836.